EBD-GROUP
17.11.2014 19:04:23 CET | Business Wire | Pressemeddelelse
The 20th anniversary edition of BIO-Europe® international partnering conference wrapped up last week, November 3–5, in Frankfurt, Germany, at the Portalhaus Messe Frankfurt conference center.
The conference attracted over 3,200 leading dealmakers from 54 countries comprising 1,786 companies made up of biotech, large and midsize pharma, and finance along with emerging companies. There were approximately 18,000 one-to-one partnering meetings and 4,065 licensing opportunities on offer, an all-time record. In addition, there were 162 company presentations and 98 exhibitors at the event.
BIO-Europe is a unique industry event, where delegates from all parts of the biotechnology value chain come to quickly identify, engage and enter into strategic relationships that drive their businesses successfully forward. Investment and collaboration opportunities developed in prior BIO-Europe conferences have produced many highly successful and historic business partnerships that resulted in life-saving drugs for patients.
“This year marked the 20th anniversary of BIO-Europe, and it was our most successful event to date in terms of the caliber of attendees, the number of partnering meetings and the sheer volume of licensing opportunities brought to the table,” said Anna Chrisman , Group Managing Director, EBD Group.
“As the home of Europe’s first biotech entrepreneur, Dr. Emil von Behring, it made sense for the 20th anniversary of BIO-Europe to take place in Hessen,” said Dr. Rainer Waldschmidt , the CEO of Hessen Trade & Invest. “Frankfurt is an ideal location for drug development companies, and we were pleased to welcome a vast array of biotech and large pharma industry leaders to experience Frankfurt’s strength in and dedication to life science innovation.”
Next year’s BIO-Europe event will be held November 2–4, 2015 in Munich, Germany .
Video coverage and exclusive interviews from BIO-Europe are available on the BIO-Europe web site and on partnering360® . BIO-Europe is Europe's largest partnering conference serving the global biotechnology industry.
At BIO-Europe, companies participated in one-to-one partnering meetings facilitated by EBD Group’s highly reputable partneringONE® platform.
About BIO-Europe ® 2014:
BIO-Europe is Europe's largest partnering conference serving the global biotechnology industry.
Delegates from all parts of the biotechnology value chain attended BIO-Europe to quickly identify, engage and enter into strategic relationships that drive their businesses successfully forward. Investment and collaboration opportunities developed in prior BIO-Europe conferences have produced many highly successful business partnerships.
Join conversations about BIO-Europe 2014 on Twitter: twitter.com/ebdgroup (hashtag: No. BEU14). Or log on to the Life Science Partnering discussion forum on partnering360. The Group is your go-to discussion forum for news and topics related to BIO-Europe.
About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:
- BIO-Europe ® and BIO-Europe Spring ®, Europe’s largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
- BioPharm America ™, the fastest growing partnering event in North America
- Biotech Showcase ™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
- BioEquity Europe , the investor conference co-organized with BioCentury Publications and BIO
- ChinaBio® Partnering Forum , the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® LLC
- Medtech Partnering Forum, EBD Group’s partnering event for the innovative medical technology industry
- The Global Impact Forum ™, a unique and innovative partnering conference in impact investing and venture philanthropy.
EBD Group’s sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.
EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world.
EBD Group has offices in the USA and Europe.
For more information please visit www.ebdgroup.com .
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20141117006287/en/
Contact:
EBD Group
Erin Righetti
+1 760 930 0500
erighetti@ebdgroup.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
FlightSafety International Receives FAA Approval for Virtual Aircraft Preflight Inspection with Evaluation Mode6.5.2026 16:05:00 CEST | Press release
Three aircraft programs approved, with three more expected to receive approval in 2026 FlightSafety International Inc., the global leader in aviation training and simulation technology, today announced it has received Federal Aviation Administration (FAA) approval for Virtual Aircraft Preflight Inspection (VAPI) with Evaluation Mode for three aircraft training programs: the Embraer EMB-550, Gulfstream G500/G600, and Citation Latitude. This innovative capability allows pilots in initial training to complete a 3D virtual aircraft preflight inspection while in Training Mode, with the added ability to transition directly into the flight deck, followed by Evaluation Mode, that allows pilots to do their preflight check ride portion. “VAPI represents a meaningful advancement in training innovation,” said David Penney, VP of Safety, Courseware and Regulatory Affairs, FlightSafety International. “By leveraging an immersive 3D environment, it offers pilots a more engaging and practical way to de
Riskified Unveils Next-Generation AI Suite at Ascend 2026, Empowering Merchants with Unprecedented Visibility and Control Over Ecommerce Risk6.5.2026 15:00:00 CEST | Press release
New capabilities include Riskified ARIA the AI Risk Analyst, Identity Explore 2.0, and an enhanced Decision Studio, giving merchants the power to see, understand, and act on network risk intelligence like never before Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced a major leap forward in its AI platform capabilities, introducing a powerful suite of control and empowerment tools designed to give merchant fraud teams complete visibility into risk patterns and identity behavior, conversational AI-driven insights, and the ability to surgically tailor their risk strategies. The innovation suite was announced onstage at Ascend 2026, Riskified’s premier global summit series, taking place May 4-6, 2026, at the Conrad New York Downtown in Manhattan, NY. With global ecommerce continuing to expand and losses from AI-driven fraud attacks projected to spike, particularly with the rise of agentic commerce, where AI bots may conduct transactions on b
Twilio’s Next Generation Platform: An Infrastructure Layer for Every Conversation in the Agentic Era6.5.2026 15:00:00 CEST | Press release
New platform capabilities orchestrate context-rich conversations with persistent memory across multiple channels for humans and AI agentsConversation Memory, Conversation Orchestrator, Conversation Intelligence, and Agent Connect provide the nervous system for modern customer engagement Twilio (NYSE: TWLO), the infrastructure for customer engagement in the AI era, kicked off its user conference, SIGNAL, by unveiling its next generation platform capabilities for the agentic era. Generally available today, Conversation Memory, Conversation Orchestrator, Conversation Intelligence, and Agent Connect combine to turn disparate interactions into continuous, intelligent, and personal conversations across humans, agents, and systems. “The agentic era is here. Agents are joining conversations alongside the people they represent, and modern customer engagement requires an infrastructure that serves both equally,” said Khozema Shipchandler, Chief Executive Officer at Twilio. “Twilio’s new platform
Vultr, SUSE & Supermicro Debut Unified Cloud-to-Edge Architecture for Global AI Scaling6.5.2026 14:00:00 CEST | Press release
The strategic partnership bridges the gap between regional cloud and the far edge, combining ruggedized hardware and GitOps-driven Kubernetes to streamline large-scale AI deployments Vultr, the world's largest privately-held cloud infrastructure company, in collaboration with SUSE and Supermicro, today announces a strategic architectural framework designed to solve the complexities of deploying and operating AI workloads across distributed environments. As AI moves closer to the point of data creation - from manufacturing floors to retail storefronts - organizations face significant challenges in latency, cost and operational consistency. This joint initiative provides a seamless, Cloud-to-Edge pipeline that integrates high-performance hardware, localized cloud infrastructure, and unified Kubernetes management. The partnership addresses the reality that sending all data back to a central cloud is no longer viable for real-time AI. The solution breaks down the infrastructure into three
Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program6.5.2026 14:00:00 CEST | Press release
Waiv, formerly Owkin Dx, to leverage its digital pathology platform encompassing foundation models and AI methodology for ADC biomarker discovery program Waiv, formerly Owkin Dx, a Paris-based company catalyzing AI precision testing, today announced it has entered a collaboration with Daiichi Sankyo (TSE: 4568) to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) program. With deep expertise across diverse pathology and multimodal data, and a global data network spanning academic institutions, hospitals, and laboratories, Waiv has a proven track record delivering AI-powered biomarker solutions across the full drug development lifecycle. Under the collaboration, Waiv will apply its end-to-end computational pathology platform to early phase data. This includes tumor microenvironment (TME) analysis across both hematoxylin and eosin (H&E) and immunohistochemistry (IHC) stained samples, as well as biomarker discovery and outcome prediction capabilities aimed at
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum